ESSA Pharma Inc. Class Action Lawsuit - EPIX

The filed complaint alleges that ESSA Pharma Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (ii) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate cancer than defendants had led investors to believe; (iii) the M-E Combination Study, a monotherapy and combination therapy for the treatment of prostate cancer, was unlikely to meet its prespecified Phase 2 primary endpoint; (iv) accordingly, defendants had overstated masofaniten’s clinical, regulatory, and commercial prospects; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.

In order to be eligible to join the EPIX class action lawsuit, you must have incurred a loss on shares of ESSA Pharma Inc. purchased during the class period listed above.

If you suffered a loss in ESSA Pharma Inc. during the relevant time frame or pursuant to the relevant offering(s), you have until March 25, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.